Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Core Viewpoint - Jasper Therapeutics is conducting a webinar to update investors on its Chronic Urticaria data, featuring key executives including the CEO and CFO [1][2]. Group 1: Company Overview - The webinar is hosted by Jasper's Head of Investor Relations, Alex Gray, and includes presentations from CEO Jeet Mahal and acting CMO Daniel Adelman [2]. - CFO Herb Cross will be available for questions during the Q&A session following the prepared remarks [2]. Group 2: Forward-Looking Statements - The company will be making forward-looking statements based on estimates, assumptions, and current expectations regarding future events [3]. - These forward-looking statements are subject to various risks and uncertainties that could lead to actual results differing materially from those projected [3].